Novo Nordisk A/S
XBER:NOVA
Novo Nordisk A/S
XBER:NOVA
Price:
43.7
EUR
Market Cap:
€148B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Novo Nordisk A/S
XBER:NOVA
|
DK |
|
R
|
Rich Sport PCL
SET:RSP
|
TH |
|
Noodles & Co
NASDAQ:NDLS
|
US |
|
A
|
Ameresco Inc
F:4AM
|
US |
|
I
|
Impero A/S
CSE:IMPERO
|
DK |
|
CIMB Group Holdings Bhd
OTC:CIMDF
|
MY |
|
Swiss Steel Holding AG
SIX:STLN
|
CH |
|
Ryukyu Asteeda Sports Club Co Ltd
TSE:7364
|
JP |
|
Peyto Exploration & Development Corp
TSX:PEY
|
CA |
|
Dynacons Systems and Solutions Ltd
NSE:DSSL
|
IN |
|
Red 5 Ltd
ASX:RED
|
AU |
|
Trubnaya Metallurgicheskaya Kompaniya PAO
MOEX:TRMK
|
RU |
|
Wipro Ltd
NSE:WIPRO
|
IN |
|
TuSimple Holdings Inc
OTC:TSPH
|
US |
|
Hometrust Bancshares Inc
NASDAQ:HTBI
|
US |
|
NeoMedia Technologies Inc
OTC:NEOM
|
US |
|
S
|
Saxlund Group AB
STO:SAXG
|
SE |
|
Beyaz Filo Oto Kiralama AS
IST:BEYAZ.E
|
TR |
|
Golden Cross Resources Ltd
ASX:GCR
|
AU |
|
Ice Fish Farm AS
OSE:IFISH
|
NO |
Multiples-Based Value
The Multiples-Based Value of one
NOVA
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 43.7 EUR,
Novo Nordisk A/S
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NOVA Multiples-Based Value
LOCKED
Multiples Across Competitors
NOVA Competitors Multiples
Novo Nordisk A/S Competitors
Novo Nordisk A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Novo Nordisk A/S
XBER:NOVA
|
1.1T EUR | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
901.8B USD | 13.8 | 43.7 | 29.5 | 31.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
587.8B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
233B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
235.8B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
162.3B USD | 2.6 | 20.9 | 7.9 | 10.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.3B USD | 2.6 | 17.6 | 7.4 | 9.1 | |
| FR |
|
Sanofi SA
PAR:SAN
|
100.2B EUR | 2.1 | 12.8 | 10.7 | 10.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
